Q-omics provides the consensus-scored TTC38 profile across patient tissues and cancer cell-line models. TTC38 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC38 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TTC38 protein abundance shows 29,222 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where TTC38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC38 survival associations across molecular data types. TTC38 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC38 RNA expression–survival associations across cancer types. High TTC38 expression shows unfavorable associations in UVM, LGG and MESO, but favorable associations in KIRC, KIRP and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC38 RNA expression.
This table summarizes TTC38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 12. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC38 shows lower tumor expression in COAD, KIRP, KICH, BRCA, LUSC and READ. The COAD box plot shows higher TTC38 RNA expression in normal versus tumor tissue (log2 FC = −0.569, t-test p < 0.001).
This table shows molecular features associated with TTC38 in patient tissues and cancer cell lines. In patient samples, TTC38 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
